These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 9708568)

  • 1. Revised Nuclear Regulatory Commission regulations for release of patients administered radioactive materials: outpatient iodine-131 anti-B1 therapy.
    Siegel JA
    J Nucl Med; 1998 Aug; 39(8 Suppl):28S-33S. PubMed ID: 9708568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A practical methodology for patient release after tositumomab and (131)I-tositumomab therapy.
    Siegel JA; Kroll S; Regan D; Kaminski MS; Wahl RL
    J Nucl Med; 2002 Mar; 43(3):354-63. PubMed ID: 11884495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outpatient treatment with (131)I-anti-B1 antibody: radiation exposure to family members.
    Rutar FJ; Augustine SC; Colcher D; Siegel JA; Jacobson DA; Tempero MA; Dukat VJ; Hohenstein MA; Gobar LS; Vose JM
    J Nucl Med; 2001 Jun; 42(6):907-15. PubMed ID: 11390555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonmyeloablative iodine-131 anti-B1 radioimmunotherapy as outpatient therapy.
    Gates VL; Carey JE; Siegel JA; Kaminski MS; Wahl RL
    J Nucl Med; 1998 Jul; 39(7):1230-6. PubMed ID: 9669400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility and safety of outpatient Bexxar therapy (tositumomab and iodine I 131 tositumomab) for non-Hodgkin's lymphoma based on radiation doses to family members.
    Rutar FJ; Augustine SC; Kaminski MS; Wahl RL; Siegel JA; Colcher D
    Clin Lymphoma; 2001 Dec; 2(3):164-72. PubMed ID: 11779293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iodine-131 anti-B1 antibody therapy in non-Hodgkin's lymphoma: dosimetry and clinical implications.
    Wahl RL
    J Nucl Med; 1998 Aug; 39(8 Suppl):1S. PubMed ID: 9708563
    [No Abstract]   [Full Text] [Related]  

  • 7. The need for better methods to determine release criteria for patients administered radioactive material.
    Sparks RB; Siegel JA; Wahl RL
    Health Phys; 1998 Oct; 75(4):385-8. PubMed ID: 9753361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health physics consequences of out-patient treatment of non-Hodgkin's lymphoma with 131I-radiolabeled anti-B1 antibody.
    Ryan MT; Spicer KM; Frei-Lahr D; Samei E; Frey GD; Hargrove H; Bloodworth G
    Health Phys; 2000 Nov; 79(5 Suppl):S52-5. PubMed ID: 11045510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial results for Hybrid SPECT--conjugate-view tumor dosimetry in 131I-anti-B1 antibody therapy of previously untreated patients with lymphoma.
    Koral KF; Dewaraja Y; Li J; Barrett CL; Regan DD; Zasadny KR; Rommelfanger SG; Francis IR; Kaminski MS; Wahl RL
    J Nucl Med; 2000 Sep; 41(9):1579-86. PubMed ID: 10994741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody.
    Kaminski MS; Zasadny KR; Francis IR; Milik AW; Ross CW; Moon SD; Crawford SM; Burgess JM; Petry NA; Butchko GM
    N Engl J Med; 1993 Aug; 329(7):459-65. PubMed ID: 7687326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TEDE per cumulated activity for family members exposed to adult patients treated with 131I.
    Han EY; Lee C; Bolch WE
    Radiat Prot Dosimetry; 2013; 153(4):448-56. PubMed ID: 22821723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-specific whole-body dosimetry: principles and a simplified method for clinical implementation.
    Wahl RL; Kroll S; Zasadny KR
    J Nucl Med; 1998 Aug; 39(8 Suppl):14S-20S. PubMed ID: 9708566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Licensee over-reliance on conservatisms in NRC guidance regarding the release of patients treated with 131I.
    Siegel JA; Marcus CS; Stabin MG
    Health Phys; 2007 Dec; 93(6):667-77. PubMed ID: 17993847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iodine-131 anti-B1 antibody for B-cell lymphoma: an update on the Michigan Phase I experience.
    Wahl RL; Zasadny KR; MacFarlane D; Francis IR; Ross CW; Estes J; Fisher S; Regan D; Kroll S; Kaminski MS
    J Nucl Med; 1998 Aug; 39(8 Suppl):21S-27S. PubMed ID: 9708567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy for non-Hodgkin's lymphoma: an opportunity for pharmaceutical care in a specialty practice.
    Augustine SC; Norenberg JP; Colcher DM; Vose JM; Gobar LS; Dukat VJ; Hohenstein MA; Rutar FJ; Jacobson DA; Tempero MA
    J Am Pharm Assoc (Wash); 2002; 42(1):93-100. PubMed ID: 11833524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic response of non-Hodgkin's lymphoma to 131I-anti-B1 radioimmunotherapy: evaluation with FDG PET.
    Torizuka T; Zasadny KR; Kison PV; Rommelfanger SG; Kaminski MS; Wahl RL
    J Nucl Med; 2000 Jun; 41(6):999-1005. PubMed ID: 10855624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishing an institutional model for the administration of tositumomab and iodine I 131 tositumomab.
    Hohenstein MA; Augustine SC; Rutar F; Vose JM
    Semin Oncol; 2003 Apr; 30(2 Suppl 4):39-49. PubMed ID: 12728406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Centralized radiolabeling of antibodies for radioimmunotherapy.
    Colcher D
    J Nucl Med; 1998 Aug; 39(8 Suppl):11S-13S. PubMed ID: 9708565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma.
    Juweid ME; Stadtmauer E; Hajjar G; Sharkey RM; Suleiman S; Luger S; Swayne LC; Alavi A; Goldenberg DM
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3292s-3303s. PubMed ID: 10541378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
    DeNardo GL; DeNardo SJ; Shen S; DeNardo DA; Mirick GR; Macey DJ; Lamborn KR
    J Nucl Med; 1999 Aug; 40(8):1317-26. PubMed ID: 10450684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.